öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÇØÐñƽ
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º621

ËùÊôԺУ£ºÄÏ»ª´óѧ
ËùÊôԺϵ£ºÒ©Ñ§ÓëÉúÎï¿ÆѧѧԺ
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Ñ§


ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºqinxuping@sohu.com
ͨѶµØÖ·£ººâÑôÊÐÄÏ»ª´óѧҩѧϵ


¸öÈ˼òÊö :
2001Äê5Ô»ñÖлªÈËÃñ¹²ºÍ¹ú¸ßУ¿Æ¼¼Ò»µÈ½±£¨Ö¤ÊéºÅ2000-042£©£»2005Äê8Ô»ñºþÄÏÊ¡¿Æ¼¼½ø²½¶þµÈ½± £¨Ö¤Êé±àºÅ **-2-03£©£»2006Äê»ñÄÏ»ª´óѧ´´Ð½ø²½£»2007Äê1Ô»ñ½ÌÓý²¿¶þµÈ½±£¨Ö¤ÊéºÅ2006-085£©£»2010ÄêºþÄÏÊ¡×ÔÈ»¿Æѧ½±£¨Ö¤ÊéºÅ**£©

¿ÆÑй¤×÷ :
1988.07¡ª1995.07£¬³¤ÖÎҽѧԺÖú½Ì¡£1998.08¡ª2000.08£¬³¤ÖÎҽѧԺ½²Ê¦¡£ 2003.09¡ª ÖÁ½ñ£¬ ÄÏ»ª´óѧҩѧϵ½ÌÊÚ¡¢Ë¶µ¼¡£ÆÚ ¿¯-> ÇØÐñƽ£¬Ð»ºìºì¹â£¬Íõ࣬Öܺêå°. Effect of gene-dosage of CYP2C19 on the metabolism of diazepam in Chinese subjects. Clinic Pharmacol & Thur 1999 66(6): 642-626.ÆÚ ¿¯-> ÇØÐñƽ£¬ Ò¶·å, Áζ˷¼, ÀîÔª½¨, Involvement of CGRP in depressor effect of losartan or perindopril in rats Eur. J. Pharmacology 2003 464(1): 63-67. ÆÚ ¿¯-> ÇØÐñƽ£¬ Ye F, Hu CP, et al. Effect of calcitonin gene-related peptide on angiotensin II-induced proliferation of rat vascular smooth muscle cells, Eur. J. Pharmacology. 2004 488, 45-49.ÆÚ ¿¯-> ÇØÐñƽ£¬ ÔøãôÓî, ³ÂÇåȪ, Áζ˷¼, ÀîÔª½¨. Calcitonin gene-related peptide-mediated depressor effect and inhibiting vascular hypertrophy of rutaecarpine in renovascular hypertensive rats. J Cardiovac PharmacolTM 2007 50: 654-659.ÆÚ ¿¯-> ÇØÐñƽ£¬ÔøãôÓÌﺣºì,µËË®Ðã, Èο¡·¼, Ö£Ôª±ó, Áζ˷¼£¬ÀîÔª½¨. INVOLVEMENT OF PROLYLCARBOXYPEPTIDASE IN THE EFFECT OF RUTAECARPINE ON THE REGRESSION OF MESENTERIC ARTERY HYPERTROPHY IN RENOVASCULAR HYPERTENSIVE RATS. Clin Exp Pharmacol Physiol. 2009£»36£º319-324. ÆÚ ¿¯-> ÚÈÚS£¬´÷ÖÒ£¬ÁõÑå÷£¬Ìﺣºì£¬µËË®Ð㣬³ÂÁÙϪ£¬Wang HD, ÇØÐñƽ*. Inhibitory Effects of CGRP on Vascular Smooth Muscle Cell Proliferation: Role of Caveolae/ caveolin-1/ ERK1/2 Signal Pathway[J], Progress in Biochemistry and Biophysics, 2013£¬40(5): 445 ¨C 53.ÆÚ ¿¯-> Ìƽ­Çí£¬Ëï·É£¬ÍôìÏ»ª, ³ÂÁÙϪ, Yao CH, ¸¶Ð¡ÇÙ, ÕÅÁÁ,ÇØÐñƽ*. The role of caveolae in regulating calcitonin receptor-like receptor subcellular distribution in vascular smooth muscle cells[J], Biochem. Cell Biol, 2013£¬91(5): 357-360. ÆÚ ¿¯-> Ëï·É£¬Ìƽ­Çí£¬Ö£Ôª±ó£¬ÇØÓÖ·¢£¬³ÂÁÙϪ£¬ÇØÐñƽ.¸ß±í´ïÊÜÌå»îÐÔÐÞÊε°°×1 ¶ÔѪ¹Ü½ôÕÅËØ¢òºÍ½µ¸ÆËØ»ùÒòÏà¹ØëÄÓÕµ¼µÄA10 ϸ°û½µ¸ÆËØÊÜÌåÑùÊÜÌåĤ·Ö²¼µÄÓ°Ïì ÖйúÒ©ÀíѧÓ붾ÀíѧÔÓÖ¾2013£¬27£¨2£©£º209-215.ÆÚ ¿¯-> ÇØÓÖ·¢, Ìﺣºì, Ëï ·É, ÇØÐñƽ. ÂÈɳ̹¶ÔÁ½ÉöÒ»¼Ð¸ßѪѹ´óÊóÉöÔàµÄ±£»¤×÷Óü°PRCP-¼¤ëÄÊÍ·Åøµ÷½ÚÖáµÄÓ°Ïì ҩѧѧ±¨£¨Acta Pharmaceutica Sinica£© 2013, 48 (1): 59?65ÆÚ ¿¯-> ÀîÏæºê£¬ÇØÓÖ·¢£¬³Â¸ù£¬ÑîÏþÇ࣬ÇØÐñƽ. ¸¬°±õ£ôÈ»ùëÄø½éµ¼ÂÈɳ̹¶Ô¸ßѪѹģÐÍ´óÊóѪ¹ÜÖع¹µÄÒÖÖÆ×÷ÓÃÑо¿. ÖйúÒ©·¿£¬2013£¬24£¨13£©£º1168-1171.ÆÚ ¿¯-> ÁõÑå÷£¬ÅíºçÑÞ£¬¹ù·æ£¬È«º£Ñ࣬Âæ¾µåú£¬ÇØÐñƽ* ÊÜÌå³É·Öµ°°×ÔÚ½µ¸ÆËØ»ùÒòÏà¹ØëĺÍѪ¹Ü½ôÕÅËØII¶ÔѪ¹Üƽ»¬¼¡Ï¸°ûѪ¹Ü¹ýÑõ»¯Îïø1±í´ïµ÷¿ØÖеÄ×÷ÓÃÉúÀíѧ±¨ 2015, 67(2): 193¨C200ÖÐÄÏҽѧ¿ÆѧÔÓÖ¾±à¼­²¿Ö÷ÈΣ¬ºþÄÏÊ¡²¡ÀíÉúÀíÐÄѪ¹ÜöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬ºþÄÏÊ¡Ò©ÀíѧÐÄѪ¹ÜöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ£¬¹ú¼ÊÐÄÔಡѧ»áÖйú·Ö¹¤»á»áÔ±¡£»ÆÕýÃ÷µÈÖ÷±à ÇØÐñƽµÈ ¸±Ö÷±à ¡¶ÁÙ´²Ò©Àíѧ¡·£¬£¨¹©È«¹úרÉý±¾»¤ÀíöλÔÓéÀֵǼÈë¿ÚÏÂÔØÓã©£¨±±¾©¾üÒ½³ö°æÉç 2004Äê1Ô³ö°æ£©£»»ÆÕýÃ÷µÈÖ÷±à ÇØÐñƽµÈ ¸±Ö÷±à ҽѧÊÔÌ⾫½â´ÔÊ顶ҩÀíѧ¡·£¨±±¾©¾üÒ½³ö°æÉç 2005Äê1Ô³ö°æ£©£»³ÂÁÙϪ, ÇØÐñƽ,Ôø¸ß·å.Ö÷±à.ÉöËØ-Ѫ¹Ü½ôÕÅËØϵͳҩÀíÓëÁÙ´².ÖйúÒ½Ò©¿Æ¼¼³ö°æÉç,±±¾©:2011µÚ1°æ.³ÂÁÙϪ£¬ÇØÐñƽ£¬»ÆÇïÁÖ£¬Ö÷±à. Ѫ¹ÜÄÚƤϸ°ûÒ©ÀíÓëÁÙ´²ÈËÃñ¾üÒ½³ö°æÉ磬 47.4 Íò×Ö£¬2012ÄêµÚÒ»°æ¡£Ò©Àíѧ£¨²Î±àË«Óï½Ì²Ä£¬µÚ8°æ£©ÖìÒÀ×»£¬ÒóÃ÷ Ö÷±à. ÈËÃñÎÀÉú³ö°æÉ磨ȫ¹ú¡°Ê®ÈýÎ塱¹æ»®½Ì²Ä£©2015Äê¡£Ò©Àíѧ£¨»¤ÀíöλÔÓéÀֵǼÈë¿ÚÏÂÔؽ̲Ä£¬µÚ4°æ£©¶­Ö¾Ö÷±à. ÈËÃñÎÀÉú³ö°æÉ磨ȫ¹ú¡°Ê®ÈýÎ塱¹æ»®½Ì²Ä£©2016Äê¡£

½ÌÓý±³¾° :
1983.09¡ª1988.07£¬É½Î÷Ò½¿Æ´óѧ£¬»ñҽѧѧʿѧλ¡£ 1995.09¡ª1998.07£¬ÖÐÄÏ´óѧҩѧԺ£¨Ô­ºþÄÏÒ½¿Æ´óѧ£©¡¢Ò©ÀíѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñҽѧ˶ʿѧλ¡£2000.09¡ª2003.05£¬ÖÐÄÏ´óѧÐÄѪ¹ÜÒ©ÀíѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñҽѧ²©Ê¿Ñ§Î»¡£2007.12¡ª2008.12£¬ÃÀ¹úÇÇÖγǴóѧÉú»¯Óë·Ö×ÓÉúÎïѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬²©Ê¿ºó¡£